Compagnie Lombard Odier SCmA’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-29,992
| Closed | -$570K | – | 630 |
|
|
2019
Q1 | $570K | Hold |
29,992
| – | – | 0.02% | 184 |
|
|
2018
Q4 | $405K | Hold |
29,992
| – | – | 0.02% | 212 |
|
|
2018
Q3 | $333K | Buy |
+29,992
| New | +$300K | 0.01% | 236 |
|
|
2017
Q1 | – | Sell |
-26,000
| Closed | -$128K | – | 910 |
|
|
2016
Q4 | $128K | Hold |
26,000
| – | – | ﹤0.01% | 490 |
|
|
2016
Q3 | $129K | Buy |
26,000
+8,000
| +44% | +$40.9K | ﹤0.01% | 530 |
|
|
2016
Q2 | $92K | Hold |
18,000
| – | – | ﹤0.01% | 583 |
|
|
2016
Q1 | $103K | Hold |
18,000
| – | – | ﹤0.01% | 614 |
|
|
2015
Q4 | $187K | Buy |
18,000
+6,000
| +50% | +$81.4K | 0.01% | 481 |
|
|
2015
Q3 | $222K | Buy |
12,000
+1,000
| +9% | +$19.3K | 0.01% | 399 |
|
|
2015
Q2 | $214K | Buy |
11,000
+3,000
| +38% | +$53.1K | 0.01% | 425 |
|
|
2015
Q1 | $141K | Buy |
8,000
+2,000
| +33% | +$33.6K | 0.01% | 574 |
|
|
2014
Q4 | $96K | Buy |
6,000
+1,000
| +20% | +$13.4K | ﹤0.01% | 551 |
|
|
2014
Q3 | $63K | Hold |
5,000
| – | – | ﹤0.01% | 704 |
|
|
2014
Q2 | $78K | Hold |
5,000
| – | – | ﹤0.01% | 700 |
|
|
2014
Q1 | $66K | Buy |
+5,000
| New | +$78.2K | ﹤0.01% | 697 |
|
Other funds holding OSIR
Compagnie Lombard Odier SCmA's OSIR Position: Q2 2019 in Review
Compagnie Lombard Odier SCmA sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q2 2019, closing a stake of 29,992 shares — an estimated $570K sold.
Compagnie Lombard Odier SCmA first reported a position in OSIR in Q1 2014 and held it in 15 quarters. The position peaked at $570K in Q1 2019. 1 fund tracked by Wall St. Rank holds OSIR as of Q2 2019.
- Compagnie Lombard Odier SCmA reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
- Compagnie Lombard Odier SCmA sold 29,992 Osiris Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $570K.
- Compagnie Lombard Odier SCmA first reported a position in Osiris Therapeutics, Inc. Common Stock in Q1 2014 and held it in 15 quarters.
- Compagnie Lombard Odier SCmA's Osiris Therapeutics, Inc. Common Stock position peaked at $570K in Q1 2019.
- 1 fund tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q2 2019.
Based on Compagnie Lombard Odier SCmA's 13F filing for Q2 2019, filed 14 Aug 2019.